804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

Authors :: A.M.M. Eggermont
M. Kicinski
C.U. Blank
M. Mandala
G.V. Long
V.G. Atkinson
S. Dalle
A.M. Haydon
A. Meshcheryakov
A. Khattak
M.S. Carlino
S.K. Sandhu
S.S. Puig Sarda
P.A. Ascierto
P. Lorigan
D. Grebennik
N. Ibrahim
S.I. Marreaud
S. Suciu
C. Robert
Source :: Annals of Oncology. 33:S912-S913
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools